BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

...South Carolina Distillery Therapeutics Hematology Stem cell transplant MLL-AF4 fusion oncogene Mouse studies suggest expression of the MLL-AF4 fusion oncogene...
BioCentury | Apr 10, 2018
Distillery Techniques

Drug platforms

...TECHNOLOGY: Cell therapy HSPCs derived from iPS cells and engineered to express the MLL-AF4 fusion oncogene could improve...
...leukemogenesis. DESCRIPTION: Induced pluripotent stem (iPS) cell-derived hematopoietic stem and progenitor cells (HSPCs) expressing the MLL-AF4 fusion oncogene...
...San Francisco, Calif. email: yw.kan@ucsf.edu Claire Quang Shanghai Jiao Tong University School of Medicine University of California San Francisco MLL-AF4 fusion oncogene...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting SYNCRIP could help treat AML. In bone marrow samples from patients, SYNCRIP levels were higher than in hematopoietic stem and progenitor...
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2); MLL-AF9 fusion oncogene

Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting MTHFD2 could help treat AML. In human AML cell lines, shRNA targeting MTHFD2 decreased proliferation and colony formation compared with scrambled shRNA....
Items per page:
1 - 4 of 4